Patents Assigned to Myriad Pharmaceuticals, Inc.
-
Publication number: 20110111025Abstract: The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.Type: ApplicationFiled: April 30, 2010Publication date: May 12, 2011Applicant: Myriad Pharmaceuticals, Inc.Inventors: Gaylen M. Zentner, James C. McRea, Mark S. Williams, Gregory T. Oerhtman, Tracy Annette Powers
-
Publication number: 20100292255Abstract: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.Type: ApplicationFiled: May 14, 2010Publication date: November 18, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: Ashok C. Bajji, Se-Ho Kim, Rajendra Tangallapally, Benjamin J. Markovitz, Richard Trovato, Mark B. Anderson, Daniel A. Wettstein, Mark D. Shenderovich
-
Publication number: 20100261739Abstract: A method of treating non-small cell lung cancer (NSCLC), and especially NSCLC that has metastasized to brain is disclosed.Type: ApplicationFiled: February 16, 2010Publication date: October 14, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventor: Mark Laughlin
-
Publication number: 20100240630Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.Type: ApplicationFiled: June 4, 2010Publication date: September 23, 2010Applicant: Myriad Pharmaceuticals, Inc..Inventors: Dange Vijay KUMAR, Kraig M. Yager, David A. Gerrish, Christophe Hoarau, Mark B. Anderson
-
Publication number: 20100216862Abstract: Novel pyrrole derivatives are disclosed as A?42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the A?42 peptide.Type: ApplicationFiled: May 6, 2010Publication date: August 26, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: Warren S. Weiner, Rachel M. Slade, Yevgeniya I. Klimova, Ruth J. Walton, Mark B. Anderson
-
Publication number: 20100216751Abstract: The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.Type: ApplicationFiled: March 25, 2010Publication date: August 26, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: Jules S. Jacob, John Richards, John G. Augustine, Jaqueline S. Milea
-
Publication number: 20100184975Abstract: The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?0)NH(C1-3alkyl), -L-C(?O)N(C1-3alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3alkyl)2, -L-S(?O)2NH(C1-3alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.Type: ApplicationFiled: March 8, 2010Publication date: July 22, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: Rachel Slade, Yevgeniya Klimova, Robert J. Halter, Ashantai J. Yungai, Warren S. Weiner, Ruth J. Walton, Jon Adam Willardsen, Mark B. Anderson, Kenton Zavitz
-
Publication number: 20100137342Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions that are responsive to disruption of the vascular system, and in particular to its use in treating vascular macular degeneration.Type: ApplicationFiled: October 6, 2009Publication date: June 3, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: Mark Laughlin, Thomas L. Thorne
-
Patent number: 7714022Abstract: Novel pyrrole derivatives are disclosed as A?42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the A?42 peptide.Type: GrantFiled: March 27, 2008Date of Patent: May 11, 2010Assignee: Myriad Pharmaceuticals, Inc.Inventors: Warren S. Weiner, Rachel M. Slade, Yevgeniya I. Klimova, Ruth J. Walton, Mark B. Anderson
-
Publication number: 20100093773Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating cancer.Type: ApplicationFiled: October 6, 2009Publication date: April 15, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: MARK LAUGHLIN, Mark B. Anderson, Adam Willardsen, Chris Pleiman
-
Publication number: 20100087458Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating melanoma.Type: ApplicationFiled: October 7, 2009Publication date: April 8, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventor: Mark Laughlin
-
Publication number: 20100087457Abstract: In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a Cmax of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.Type: ApplicationFiled: October 7, 2009Publication date: April 8, 2010Applicant: Myriad Pharmaceuticals, IncInventor: MARK LAUGHLIN
-
Publication number: 20100068197Abstract: Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: ApplicationFiled: July 9, 2009Publication date: March 18, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: MARK B. ANDERSON, J. Adam Willardsen, Warren S. Weiner, Kazuyuki Suzuki, Robert J. Halter, In Chul Kim, Matthew Reeder, Ashantai Yungai
-
Patent number: 7618975Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: July 6, 2004Date of Patent: November 17, 2009Assignees: Myriad Pharmaceuticals, Inc., Cytovia, Inc.Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman
-
Patent number: 7595401Abstract: The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.Type: GrantFiled: May 14, 2007Date of Patent: September 29, 2009Assignee: Myriad Pharmaceuticals, Inc.Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
-
Publication number: 20040014763Abstract: Compounds having the following structure: 1Type: ApplicationFiled: February 14, 2003Publication date: January 22, 2004Applicant: Myriad Pharmaceuticals, Inc.Inventors: Cyprian O. Ogbu, Hwa-Ok Kim, Mark A. Blaskovich